Since the start of 2025, Beam Global’s ESS sales have seen unprecedented growth, driven by increasing adoption across various industries due to their bespoke designs, superior safety and smart battery ...

NEW YORK, March 6, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) is proud to offer a daily pre-market update directly from the NYSE Trading Floor. The NYSE became the first company to ...

John Chiminski brings more than three decades of leadership in healthcare and pharma services. He served as CEO of Catalent from 2009 to 2015, then as Chair and CEO from 2016 through 2022, and as ...

The additional sites RadNet is onboarding will help us enable more convenient access to grow scan volume in response to physician demand. It also underscores our strong relationship with this ...

Surging Demand for Insulin Dosing Precision: With 35 million insulin-dependent patients worldwide, healthcare systems are prioritizing smart syringes equipped with real-time monitoring. Mobile health ...

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each ...

Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) announces that, on February 11, 2025, the Company presented its plan of compliance to The Nasdaq ...

Report Ocean is delighted to unveil an exhaustive analysis of the Philippines Starch Recovery Systems Market, presenting a detailed exploration of its various dimensions from 2018 to 2032. Our ...

Elisa Industriq is part of Elisa, a pioneer in telecommunications and digital services headquartered in Finland. Our shared mission is a sustainable future through digitalization. Elisa Industriq ...

NB Private Equity Partners Limited. Notification of Transaction by Persons Discharging Managerial Responsibilities (PDMRs) 5 March 2025 St Peter Port, Guernsey. NB Private Equity ...

WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will ...

The Company announces that on 5 March 2025 it bought back 10,000 of its own shares, to be held as treasury shares, at an average price of 1317 pence per share. Further details are set out below: ...